Blueprint Medicines’ Ayvakit (avapritinib) is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.
https://www.pharmalive.com/wp-content/uploads/2022/05/ReutersFDAlogo5-23-2022.webp7401200BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-17 10:11:482022-08-17 10:12:43Positive Data Back Blueprint’s Bid for sNDA in Systemic Mastocytosis